323 results
Page 6 of 17
6-K
EX-99.1
9v5taq8abke a7p1
30 Mar 20
Current report (foreign)
10:29am
6-K
EX-99.1
16d1t3 bdxc4stp
3 Feb 20
If approved, Dupixent would be the first biologic medicine available in the U.S. for these children
9:45am
CORRESP
aqb ncnvf
14 Jan 20
Correspondence with SEC
12:00am
CORRESP
lcs5p an9k0199
7 Jan 20
Correspondence with SEC
12:00am
SC TO-T
EX-99
ru933iv2jl
27 Dec 19
Third party tender offer statement
5:27pm
UPLOAD
40kqqvi cyfr
20 Dec 19
Letter from SEC
12:00am
6-K
EX-99.1
1o7jo2
11 Dec 19
Current report (foreign)
8:26am
6-K
EX-99.1
gznnyi kz
10 Dec 19
Sanofi CEO unveils new strategy to drive innovation and growth
11:13am
6-K
EX-99.3
b7r9xph
31 Oct 19
Current report (foreign)
1:14pm
6-K
EX-10.1
12qri8jmba
31 Oct 19
Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation
6:48am
6-K
EX-99.3
wy42a9
15 Oct 19
One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology
1:43pm
6-K
EX-99.1
fgyay2unlefw
3 Sep 19
U.S. District Court invalidates Amgen patent claims targeting PCSK9
6:35am
6-K
EX-99.2
gq66z
9 Aug 19
Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
8:22am
6-K
EX-99.1
1d33sgy2p
9 Aug 19
Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
8:22am
6-K
EX-99.1
1tbi skd1wj
29 Jul 19
Half-year Financial Report
10:41am
6-K
EX-99.2
mxpwbwwh
29 Jul 19
Half-year Financial Report
10:41am
6-K
EX-99.3
8lhqhbqj14qlu
16 Jul 19
Current report (foreign)
10:29am
6-K
EX-99.2
ssun7ge3b twfvxa
16 Jul 19
Current report (foreign)
10:29am